Aligos Therapeutics (NASDAQ:ALGS) Research Coverage Started at Westpark Capital

Westpark Capital started coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report sent to investors on Thursday morning,Benzinga reports. The firm issued a buy rating and a $48.00 target price on the stock.

Other research analysts have also recently issued reports about the company. Jefferies Financial Group started coverage on Aligos Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $48.00 price objective for the company. Wall Street Zen lowered shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Wednesday, January 21st. UBS Group assumed coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Aligos Therapeutics Stock Down 5.4%

Shares of Aligos Therapeutics stock opened at $6.66 on Thursday. Aligos Therapeutics has a 52-week low of $3.76 and a 52-week high of $13.69. The company has a market capitalization of $41.23 million, a P/E ratio of -0.78 and a beta of 2.67. The company has a 50 day moving average of $7.30 and a 200 day moving average of $8.71.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($1.91) EPS for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. As a group, research analysts anticipate that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of institutional investors have recently modified their holdings of ALGS. Geode Capital Management LLC raised its position in Aligos Therapeutics by 21.3% in the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after purchasing an additional 5,978 shares during the last quarter. Rockefeller Capital Management L.P. grew its position in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares during the last quarter. NorthCrest Asset Manangement LLC acquired a new position in Aligos Therapeutics in the third quarter valued at $98,000. Susquehanna International Group LLP purchased a new stake in shares of Aligos Therapeutics in the third quarter valued at about $99,000. Finally, LPL Financial LLC boosted its stake in shares of Aligos Therapeutics by 19.7% during the fourth quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after buying an additional 10,880 shares during the period. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.